Do analysts prefer TRAW or DRCT?

Traws Pharma currently has a consensus price target of $1.00, suggesting a potential upside of 20.77%. Given Traws Pharma's stronger consensus rating and higher possible upside, research analysts plainly believe Traws Pharma is more favorable than Direct Digital. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Traws Pharma 2 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.60 Direct Digital 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts recommend BGM or TRAW?

Traws Pharma has a consensus price target of $1.00, suggesting a potential upside of 20.77%. Given Traws Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Traws Pharma is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Traws Pharma 2 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.60

Which has preferable earnings & valuation, BGM or TRAW?

Traws Pharma has lower revenue, but higher earnings than BGM Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $26.85M 1.34 -$1.44M N/A N/A Traws Pharma $2.79M 3.02 $9.17M -$1.69 N/A

Is BGM or TRAW more profitable?

BGM Group's return on equity of 0.00% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets BGM Group N/A N/A N/A Traws Pharma N/A -913.18% -133.88%

Do analysts recommend TRAW or PYRGF?

Traws Pharma currently has a consensus target price of $1.00, indicating a potential upside of 20.77%. Given Traws Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Traws Pharma is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Traws Pharma 2 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.60 PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is TRAW or ATHA more profitable?

Athira Pharma's return on equity of -107.06% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Traws Pharma N/A -913.18% -133.88% Athira Pharma N/A -107.06% -89.89%

Traws Pharma (TRAW) Competitors

$0.83 +0.01 (+0.89%)

As of 11:47 AM Eastern

Compare

TRAW vs. DRCT, SLGL, BGM, PYRGF, and ATHA

Should you buy Traws Pharma stock or one of its competitors? MarketBeat compares Traws Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Traws Pharma include Direct Digital (DRCT), Sol-Gel Technologies (SLGL), BGM Group (BGM), PyroGenesis Canada (PYRGF), and Athira Pharma (ATHA).

How does Traws Pharma compare to Direct Digital?

Traws Pharma (NASDAQ:TRAW) and Direct Digital (NASDAQ:DRCT) are related small-cap companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Traws Pharma has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market. Comparatively, Direct Digital has a beta of 5.34, suggesting that its share price is 434% more volatile than the broader market.

Traws Pharma has higher earnings, but lower revenue than Direct Digital. Traws Pharma is trading at a lower price-to-earnings ratio than Direct Digital, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.79M	3.02	$9.17M	-$1.69	N/A
Direct Digital	$34.69M	0.06	-$18.95M	-$201.62	N/A

Traws Pharma currently has a consensus price target of $1.00, suggesting a potential upside of 20.77%. Given Traws Pharma's stronger consensus rating and higher possible upside, research analysts plainly believe Traws Pharma is more favorable than Direct Digital.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Direct Digital	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Direct Digital had 9 more articles in the media than Traws Pharma. MarketBeat recorded 10 mentions for Direct Digital and 1 mentions for Traws Pharma. Traws Pharma's average media sentiment score of 1.87 beat Direct Digital's score of -0.56 indicating that Traws Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Traws Pharma	Very Positive
Direct Digital	Negative

8.0% of Traws Pharma shares are owned by institutional investors. Comparatively, 4.0% of Direct Digital shares are owned by institutional investors. 7.6% of Traws Pharma shares are owned by company insiders. Comparatively, 25.6% of Direct Digital shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Traws Pharma has a net margin of 0.00% compared to Direct Digital's net margin of -65.75%. Direct Digital's return on equity of 0.00% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	-913.18%	-133.88%
Direct Digital	-65.75%	N/A	-59.57%

Summary

Traws Pharma beats Direct Digital on 8 of the 15 factors compared between the two stocks.

How does Traws Pharma compare to Sol-Gel Technologies?

Sol-Gel Technologies (NASDAQ:SLGL) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 8.0% of Traws Pharma shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by company insiders. Comparatively, 7.6% of Traws Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Sol-Gel Technologies has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

In the previous week, Sol-Gel Technologies had 2 more articles in the media than Traws Pharma. MarketBeat recorded 3 mentions for Sol-Gel Technologies and 1 mentions for Traws Pharma. Traws Pharma's average media sentiment score of 1.87 beat Sol-Gel Technologies' score of 0.72 indicating that Traws Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Sol-Gel Technologies	Positive
Traws Pharma	Very Positive

Traws Pharma has lower revenue, but higher earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	10.56	-$6.13M	-$0.34	N/A
Traws Pharma	$2.79M	3.02	$9.17M	-$1.69	N/A

Traws Pharma has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -5.66%. Sol-Gel Technologies' return on equity of -3.17% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%
Traws Pharma	N/A	-913.18%	-133.88%

Sol-Gel Technologies presently has a consensus target price of $197.50, suggesting a potential upside of 170.97%. Traws Pharma has a consensus target price of $1.00, suggesting a potential upside of 20.77%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, research analysts plainly believe Sol-Gel Technologies is more favorable than Traws Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Traws Pharma	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

Summary

Sol-Gel Technologies beats Traws Pharma on 12 of the 17 factors compared between the two stocks.

How does Traws Pharma compare to BGM Group?

BGM Group (NASDAQ:BGM) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

Traws Pharma has a consensus price target of $1.00, suggesting a potential upside of 20.77%. Given Traws Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Traws Pharma is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Traws Pharma	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

Traws Pharma has lower revenue, but higher earnings than BGM Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$26.85M	1.34	-$1.44M	N/A	N/A
Traws Pharma	$2.79M	3.02	$9.17M	-$1.69	N/A

BGM Group's return on equity of 0.00% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Traws Pharma	N/A	-913.18%	-133.88%

8.0% of Traws Pharma shares are owned by institutional investors. 58.7% of BGM Group shares are owned by company insiders. Comparatively, 7.6% of Traws Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

BGM Group has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

In the previous week, BGM Group and BGM Group both had 1 articles in the media. BGM Group's average media sentiment score of 1.89 beat Traws Pharma's score of 1.87 indicating that BGM Group is being referred to more favorably in the media.

Company	Overall Sentiment
BGM Group	Very Positive
Traws Pharma	Very Positive

Summary

BGM Group beats Traws Pharma on 6 of the 11 factors compared between the two stocks.

How does Traws Pharma compare to PyroGenesis Canada?

Traws Pharma (NASDAQ:TRAW) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

8.0% of Traws Pharma shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 7.6% of Traws Pharma shares are owned by company insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Traws Pharma currently has a consensus target price of $1.00, indicating a potential upside of 20.77%. Given Traws Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Traws Pharma is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Traws Pharma has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	-913.18%	-133.88%
PyroGenesis Canada	-115.14%	N/A	-60.81%

Traws Pharma has higher earnings, but lower revenue than PyroGenesis Canada. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.79M	3.02	$9.17M	-$1.69	N/A
PyroGenesis Canada	$9.14M	3.63	-$21.12M	-$0.04	N/A

In the previous week, Traws Pharma and Traws Pharma both had 1 articles in the media. Traws Pharma's average media sentiment score of 1.87 beat PyroGenesis Canada's score of 0.00 indicating that Traws Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Traws Pharma	Very Positive
PyroGenesis Canada	Neutral

Traws Pharma has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market.

Summary

Traws Pharma beats PyroGenesis Canada on 8 of the 14 factors compared between the two stocks.

How does Traws Pharma compare to Athira Pharma?

Traws Pharma (NASDAQ:TRAW) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Traws Pharma has higher revenue and earnings than Athira Pharma. Athira Pharma is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.79M	3.02	$9.17M	-$1.69	N/A
Athira Pharma	N/A	N/A	-$96.94M	-$9.68	N/A

Athira Pharma's return on equity of -107.06% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	-913.18%	-133.88%
Athira Pharma	N/A	-107.06%	-89.89%

Traws Pharma presently has a consensus target price of $1.00, indicating a potential upside of 20.77%. Athira Pharma has a consensus target price of $4.00, indicating a potential downside of 51.34%. Given Traws Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Traws Pharma is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Athira Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

8.0% of Traws Pharma shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 7.6% of Traws Pharma shares are owned by company insiders. Comparatively, 19.8% of Athira Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Traws Pharma had 1 more articles in the media than Athira Pharma. MarketBeat recorded 1 mentions for Traws Pharma and 0 mentions for Athira Pharma. Traws Pharma's average media sentiment score of 1.87 beat Athira Pharma's score of 0.00 indicating that Traws Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Traws Pharma	Very Positive
Athira Pharma	Neutral

Traws Pharma has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market. Comparatively, Athira Pharma has a beta of 2.79, indicating that its stock price is 179% more volatile than the broader market.

Summary

Traws Pharma beats Athira Pharma on 8 of the 13 factors compared between the two stocks.

Get Traws Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRAW vs. The Competition

Export

Metric	Traws Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.41M	$3.04B	$6.76B	$12.51B
Dividend Yield	N/A	1.87%	2.66%	6.22%
P/E Ratio	-0.49	19.59	25.78	24.73
Price / Sales	3.02	361.90	548.02	103.35
Price / Cash	1.08	56.85	29.14	36.96
Price / Book	-11.83	4.27	10.84	6.52
Net Income	$9.17M	$64.45M	$3.57B	$336.86M
7 Day Performance	-1.13%	3.08%	2.43%	1.31%
1 Month Performance	-43.29%	3.79%	0.76%	0.36%
1 Year Performance	-44.05%	34.58%	36.68%	30.89%

Traws Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRAW Traws Pharma	3.9173 of 5 stars	$0.83 +0.9%	$1.00 +20.8%	-42.6%	$8.41M	$2.79M	N/A	17	Positive News
DRCT Direct Digital	0.4332 of 5 stars	$2.79 -1.4%	N/A	-97.8%	$2.10M	$34.69M	N/A	60	Short Interest Increase
SLGL Sol-Gel Technologies	3.8417 of 5 stars	$73.40 +3.0%	$197.50 +169.1%	+916.5%	$200.23M	$19.39M	N/A	50
BGM BGM Group	0.7587 of 5 stars	$0.34 -0.2%	N/A	-96.9%	$33.25M	$25.10M	N/A	298	Positive News
PYRGF PyroGenesis Canada	N/A	$0.15 -3.5%	N/A	-54.8%	$32.69M	$9.14M	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRAW) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Traws Pharma (TRAW) Competitors

TRAW vs. DRCT, SLGL, BGM, PYRGF, and ATHA

How does Traws Pharma compare to Direct Digital?

Summary

How does Traws Pharma compare to Sol-Gel Technologies?

Summary

How does Traws Pharma compare to BGM Group?

Summary

How does Traws Pharma compare to PyroGenesis Canada?

Summary

How does Traws Pharma compare to Athira Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAW vs. The Competition

Traws Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Traws Pharma (TRAW) Competitors

TRAW vs. DRCT, SLGL, BGM, PYRGF, and ATHA

How does Traws Pharma compare to Direct Digital?

Which has more risk & volatility, TRAW or DRCT?

Which has better valuation & earnings, TRAW or DRCT?

Do analysts prefer TRAW or DRCT?

Does the media prefer TRAW or DRCT?

Do institutionals and insiders hold more shares of TRAW or DRCT?

Is TRAW or DRCT more profitable?

Summary

How does Traws Pharma compare to Sol-Gel Technologies?

Do institutionals and insiders hold more shares of SLGL or TRAW?

Which has more volatility & risk, SLGL or TRAW?

Does the media refer more to SLGL or TRAW?

Which has better earnings & valuation, SLGL or TRAW?

Is SLGL or TRAW more profitable?

Do analysts prefer SLGL or TRAW?

Summary

How does Traws Pharma compare to BGM Group?

Do analysts recommend BGM or TRAW?

Which has preferable earnings & valuation, BGM or TRAW?

Is BGM or TRAW more profitable?

Do institutionals and insiders hold more shares of BGM or TRAW?

Which has more volatility & risk, BGM or TRAW?

Does the media favor BGM or TRAW?

Summary

How does Traws Pharma compare to PyroGenesis Canada?

Do institutionals & insiders have more ownership in TRAW or PYRGF?

Do analysts recommend TRAW or PYRGF?

Is TRAW or PYRGF more profitable?

Which has better valuation & earnings, TRAW or PYRGF?

Does the media prefer TRAW or PYRGF?

Which has more volatility & risk, TRAW or PYRGF?

Summary

How does Traws Pharma compare to Athira Pharma?

Which has higher valuation & earnings, TRAW or ATHA?

Is TRAW or ATHA more profitable?

Do analysts prefer TRAW or ATHA?

Do institutionals & insiders have more ownership in TRAW or ATHA?

Does the media prefer TRAW or ATHA?

Which has more risk and volatility, TRAW or ATHA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAW vs. The Competition

Traws Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools